Publications by authors named "Mirte van der Heijden"
T cell-focused cancer immunotherapy including checkpoint inhibitors and cell therapies has been rapidly evolving over the past decade. Nevertheless, there remains a major unmet medical need in oncology generally and immuno-oncology specifically. We have constructed an oncolytic adenovirus, Ad5/3-E2F-d24-aMUC1aCD3-IL-2 (TILT-322), which is armed with a human aMUC1aCD3 T cell engager and IL-2.
View Article and Find Full Text PDFArticle Synopsis
- Researchers discovered that 4-octyl itaconate (4-OI) can enhance the effects of an oncolytic virus, VSVΔ51, in resistant cancer cells and models, leading to better treatment outcomes.
- The mechanism involves 4-OI suppressing antiviral immunity in cancer cells by modifying specific proteins, which suggests that combining metabolite-derived drugs with oncolytic viruses could significantly improve cancer treatment.
Purpose: TILT-123 (igrelimogene litadenorepvec) is an oncolytic adenovirus armed with TNFa and IL2, designed to induce T-cell infiltration and cytotoxicity in solid tumors.
Patients And Methods: TUNIMO (NCT04695327) was a single-arm, multicenter phase I dose-escalation trial designed to assess the safety of TILT-123 in advanced solid cancers refractory to standard therapy. Patients received intravenous and intratumoral TILT-123.